课题基金 / 基金详情

Cancer Control

Cancer Control
癌症控制
批准号:
10589911
负责人:
Matthew J Carpenter
金额:
$5.06万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2024-03-31
关键词:
AcademyAddressAdvanced Glycosylation End ProductsAfrican AmericanAfrican American populationAreaAwardBasic ScienceBehavioralBehavioral SciencesBiologicalBreast Cancer PatientCancer BurdenCancer CenterCancer Center Support GrantCancer ControlCancer Control Research ProgramCancer EtiologyCancer PatientCaringCervicalClinicalClinical TrialsCollaborationsCommunitiesComplexDataDevelopmentDiagnosticDiscipline of NursingDissemination and ImplementationDoctor of PhilosophyEnrollmentEvaluationEvidence based interventionExclusionFacultyFaculty RecruitmentFosteringFundingFutureGeneticGenetsGoalsGrantHead and Neck CancerHealthHealth PolicyHealthcare SystemsHistorically Black Colleges and UniversitiesHuman Papilloma Virus VaccinationHuman Papilloma Virus VaccineIncidenceIndividualInpatientsInternationalInterventionIntervention StudiesIntervention TrialInvestmentsJournalsK-Series Research Career ProgramsLeadLeadershipMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of prostateMedicalMedicineMentorsMinority MenMissionMolecularMolecular EpidemiologyMorbidity - disease rateNational Institute on Minority Health and Health DisparitiesNeurocognitiveOutcomeOutcomes ResearchPeer ReviewPhysiciansPopulation ResearchPopulation SciencesPredisposing FactorPredispositionPreventionPrevention strategyPsychiatryPsychological FactorsPublic HealthPublic PolicyPublicationsPublishingResearchResearch PersonnelResource SharingRisk FactorsScientistServicesShapesSmokingSourceSouth CarolinaStrategic PlanningSupportive careSystemTimeTobacco Use CessationTrainingTranslatingTranslational ResearchUnited States National Institutes of HealthUniversitiesWorkaddictionbasecancer health disparitycare deliverycareer developmentclinical riskcollegecommunity based practicecost effectiveepidemiology studyevidence basegenetic risk factorhealth disparityhospital readmissionimprovedimproved outcomeinnovationinsightinter-institutionallow socioeconomic statusmale healthmedicine manmemberminority healthminority health disparityminority patientmortalitynicotine vapornovelpharmacologicphase II trialpopulation healthprecision medicineprogramspsychologicpublic policy on tobaccorandomized, controlled studyrecruitrelapse risksmoking addictionsmoking cessationsmoking relapsesocialsocial epidemiologysocial factorssurvivorshiptobacco controlvaccine acceptance

项目摘要

项目成果

Matthew J Carpenter的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CANCER CONTROL PROGRAM: SUMMARY The Cancer Control (CC) Program fosters population sciences research that seeks to reduce cancer morbidity and mortality in South Carolina while providing novel, evidence-based cancer control interventions that can be applied beyond the state’s borders. Guided by two cross-cutting themes, cancer disparities and tobacco control, CC members have made marked progress in all areas. To address cancer health disparities, CC members es- tablished a precision medicine center to dissect and address the complex genetic, psychological, and social fac- tors impacting cancer disparities, established systems to increase the accrual of minority patients to clinical trials, and identified advanced glycation endproducts as a pharmacological target for a phase 2 trial in African Ameri- can cancer patients of low socioeconomic status. Advances in tobacco control include identification of neu- rocognitive mechanisms that increase smoking relapse risk, development of pharmacological strategies for smoking cessation, and implementation of an inpatient stop smoking service that reduces hospital readmissions. Co-led by Chanita Hughes-Halbert, PhD and Matthew J. Carpenter, PhD, national leaders in minority health and cancer disparities and tobacco control, respectively, the program comprises 25 population health and phy- sician-scientist faculty members from nine departments. Excluding career development and training grants, the annual total direct peer-reviewed funding base for the program is $4.4M, an increase of 37.5% since the prior renewal, with $1.6M from the NCI, $2.1M from other NIH awards, and $0.6M from other peer-reviewed sources. CC members foster collaborative research and lead several new large center awards and cooperative grants, including an NCI P01, NCI UG1, NCI U54, and an NIMHD U54. Through well-established training pipe- lines, members invest in mentoring and, as a result, six junior faculty hold peer-reviewed career development awards. During the past five years, CC members authored 183 cancer-relevant publications, of which 83% were collaborative with Hollings Cancer Center members in CC and other research programs. The exceptional quality of the program’s research is reflected by transformative insights into the causes of cancer disparities, discovery of molecular and behavioral risk factors underlying cancer susceptibility, and evaluation of evidence- based approaches to encourage tobacco cessation. These have been published in top-tier journals such as Lancet, Lancet Oncol, N Engl J Med, J Med Genet, Am J Respir and Crit Care Med, JAMA Psychiatry, J Clin Oncol, and Nat Genet. CC members launched innovative trial interventions in the areas of care delivery, pre- vention, supportive care, improved diagnostics, and survivorship, with 842 individuals enrolled in interventional studies in 2017. With continued strong faculty recruitment, mentoring of emerging independent scientists, and development of transdisciplinary team-based interprogrammatic initiatives, the CC Program is exceptionally well equipped to lead efforts in reducing the cancer burden in South Carolina.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A clinical trial of adaptive treatment for early smoking cessation relapse
A Translational Randomized Clinical Trial of Varenicline Sampling to Promote Smoking Cessation and Scalable Treatment Dissemination
A Translational Randomized Clinical Trial of Varenicline Sampling to Promote Smoking Cessation and Scalable Treatment Dissemination
A Translational Randomized Clinical Trial of Varenicline Sampling to Promote Smoking Cessation and Scalable Treatment Dissemination
海外基金